Synaptogenix 8/15/2025 Earnings Report

Synaptogenix EPS Results

• Actual EPS: -$11.26
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Synaptogenix Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Synaptogenix Announcement Details

• Date: 8/15/2025
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

Synaptogenix (NASDAQ:TAOX) operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.